Enzymatic Evidence of Impaired Reperfusion in Diabetic Patients After Thrombolytic Therapy for Acute Myocardial Infarction: a Role for Plasminogen Activator Inhibitor?

Overview

Journal Br Heart J

Specialty Cardiology & Vascular Diseases

Date 1993 Dec 1

PMID 8280517

Citations 8

Authors

R P Gray

J S Yudkin

D L PATTERSON

Affiliations

Soon will be listed here.

Abstract

Objective: To compare the activity of plasminogen activator inhibitor (PAI-1) in diabetic and non-diabetic patients admitted with acute myocardial infarction and to determine whether PAI-1 activity influences reperfusion after thrombolytic therapy.

Design: Prospective study of patients admitted with acute myocardial infarction.

Setting: District general hospital.

Main Outcome Measures: Reperfusion assessed by time to peak release of creatine kinase-MB isoenzyme.

Results: Baseline PAI-1 activity and antigen concentrations were significantly higher in diabetic patients (n = 45) than in non-diabetic patients (n = 110) (24.6 (6.9) v 18.6 (7.9) AU/ml (AU = arbitrary units) (p = 0.0001) and 58.8 (13.1-328.8) v 41.0 (10.9-125.4) ng/ml (p = 0.004). Time to peak release of creatine kinase-MB was calculated in 123 (80%) patients. In 98 who received thrombolytic therapy the median time to peak enzyme release was 15.5 h (7.5-24 h) in diabetic patients (n = 26) and 12 h (5-26 h) in non-diabetic patients (n = 72) (p = 0.005). In those with a time to peak release of < or = 12 h, indicating likely successful reperfusion, PAI-1 activity was 17.5 (7.8) AU/ml compared with 22.8 (7.7) AU/ml in those with a time to peak release of > 12 h (p = 0.001). In multiple regression analysis both diabetes (p = 0.0001) and PAI-1 activity at admission (p = 0.029) were independently related to successful reperfusion. In 13 patients with evidence of reinfarction in hospital PAI-1 activity on day 3 was 26.7 (6.4) AU/ml compared with 21.7 (6.3) AU/ml in those without evidence of reinfarction (p = 0.032).

Conclusion: Both raised PAI-1 activity on admission and diabetes were associated with a reduced likelihood of enzymatic evidence of reperfusion after thrombolytic therapy. Increased PAI-1 activity on day 3 was associated with an increased risk of reinfarction. Diabetic patients had higher PAI-1 activity on admission. This may partly explain their reduced likelihood of reperfusion.

Citing Articles

Association between plasminogen activator inhibitor-1 and cardiovascular events: a systematic review and meta-analysis.

Jung R, Motazedian P, Ramirez F, Simard T, Di Santo P, Visintini S Thromb J. 2018; 16:12.

PMID: 29991926 PMC: 5987541. DOI: 10.1186/s12959-018-0166-4.

PPAR-γ receptor agonists-a review of their role in diabetic management in Trinidad and Tobago.

Smith S Mol Cell Biochem. 2016; 263(1):189-210.

PMID: 27520678 DOI: 10.1023/B:MCBI.0000041861.79585.4b.

Assessment of coronary heart diseases in diabetics in al-Madinah al-Munawarah.

Al-Nozha O, Mojadadi M, Mosaad M, El-Bab M Int J Gen Med. 2012; 5:143-9.

PMID: 22393300 PMC: 3292397. DOI: 10.2147/IJGM.S27373.

The influence of acute-phase levels of haemostatic factors on reperfusion and mortality in patients with acute myocardial infarction treated with streptokinase.

Nilsson J, Boman K, Jansson J, Nilsson T, Naslund U J Thromb Thrombolysis. 2007; 26(3):188-95.

PMID: 17721741 DOI: 10.1007/s11239-007-0086-9.

The effect of high plasma levels of angiotensin-converting enzyme (ACE) and plasminogen activator inhibitor (PAI-1) on the reperfusion after thrombolytic therapy in patients presented with acute myocardial infarction.

El Menyar A, Altamimi O, Gomaa M, Fawzy Z, Abdel Rahman M, Bener A J Thromb Thrombolysis. 2006; 21(3):235-40.

PMID: 16683215 DOI: 10.1007/s11239-006-5484-x.

References

Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C . Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet. 1987; 2(8549):3-9. DOI: 10.1016/s0140-6736(87)93050-9. View

Eisenberg P, Sherman L, Jaffe A . Paradoxic elevation of fibrinopeptide A after streptokinase: evidence for continued thrombosis despite intense fibrinolysis. J Am Coll Cardiol. 1987; 10(3):527-9. DOI: 10.1016/s0735-1097(87)80194-8. View

White H, Norris R, Brown M, Takayama M, Maslowski A, Bass N . Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med. 1987; 317(14):850-5. DOI: 10.1056/NEJM198710013171402. View

Vague P, Juhan-Vague I, Alessi M, Badier C, Valadier J . Metformin decreases the high plasminogen activator inhibition capacity, plasma insulin and triglyceride levels in non-diabetic obese subjects. Thromb Haemost. 1987; 57(3):326-8. View

Kruithof E, Nicolosa G, Bachmann F . Plasminogen activator inhibitor 1: development of a radioimmunoassay and observations on its plasma concentration during venous occlusion and after platelet aggregation. Blood. 1987; 70(5):1645-53. View

Declerck P, Alessi M, Verstreken M, Kruithof E, Juhan-Vague I, Collen D . Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 1988; 71(1):220-5. View

Fitzgerald D, CATELLA F, Roy L, FitzGerald G . Marked platelet activation in vivo after intravenous streptokinase in patients with acute myocardial infarction. Circulation. 1988; 77(1):142-50. DOI: 10.1161/01.cir.77.1.142. View

Auwerx J, Bouillon R, Collen D, Geboers J . Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis. 1988; 8(1):68-72. DOI: 10.1161/01.atv.8.1.68. View

Yudkin J, Oswald G . Determinants of hospital admission and case fatality in diabetic patients with myocardial infarction. Diabetes Care. 1988; 11(4):351-8. DOI: 10.2337/diacare.11.4.351. View

10.

Katus H, DIEDERICH K, Scheffold T, Uellner M, Schwarz F, Kubler W . Non-invasive assessment of infarct reperfusion: the predictive power of the time to peak value of myoglobin, CKMB, and CK in serum. Eur Heart J. 1988; 9(6):619-24. DOI: 10.1093/oxfordjournals.eurheartj.a062551. View

11.

Kwaan H, Colwell J, Cruz S, Suwanwela N, DOBBIE J . Increased platelet aggregation in diabetes mellitus. J Lab Clin Med. 1972; 80(2):236-46. View

12.

Sobel B, Bresnahan G, Shell W, YODER R . Estimation of infarct size in man and its relation to prognosis. Circulation. 1972; 46(4):640-8. DOI: 10.1161/01.cir.46.4.640. View

13.

Fuller J, Keen H, Jarrett R, Omer T, Meade T, Chakrabarti R . Haemostatic variables associated with diabetes and its complications. Br Med J. 1979; 2(6196):964-6. PMC: 1596588. DOI: 10.1136/bmj.2.6196.964. View

14.

Grande P, Naestoft J, Christiansen C . An easy and reliable estimation of acute myocardial infarct size from serum CK-MB measurements. Eur J Cardiol. 1980; 11(1):71-7. View

15.

Schroder R, Biamino G, von Leitner E, Linderer T, Bruggemann T, Heitz J . Intravenous short-term infusion of streptokinase in acute myocardial infarction. Circulation. 1983; 67(3):536-48. DOI: 10.1161/01.cir.67.3.536. View

16.

Boyle D, Barber J, McIlmoyle E, Salathia K, Evans A, Cran G . Effect of very early intervention with metoprolol on myocardial infarct size. Br Heart J. 1983; 49(3):229-33. PMC: 481293. DOI: 10.1136/hrt.49.3.229. View

17.

Ong L, Reiser P, Coromilas J, SCHERR L, Morrison J . Left ventricular function and rapid release of creatine kinase MB in acute myocardial infarction. Evidence for spontaneous reperfusion. N Engl J Med. 1983; 309(1):1-6. DOI: 10.1056/NEJM198307073090101. View

18.

Schwartz H, Leiboff R, Katz R, Wasserman A, Bren G, VARGHESE P . Arteriographic predictors of spontaneous improvement in left ventricular function after myocardial infarction. Circulation. 1985; 71(3):466-72. DOI: 10.1161/01.cir.71.3.466. View

19.

Kruithof E, Bachmann F . Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemost. 1986; 55(2):201-5. View

20.

Oswald G, Yudkin J . Hyperglycaemia following acute myocardial infarction: the contribution of undiagnosed diabetes. Diabet Med. 1987; 4(1):68-70. DOI: 10.1111/j.1464-5491.1987.tb00833.x. View